[go: up one dir, main page]

MX2019004030A - Inhibidores del receptor de glucocorticoides. - Google Patents

Inhibidores del receptor de glucocorticoides.

Info

Publication number
MX2019004030A
MX2019004030A MX2019004030A MX2019004030A MX2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A MX 2019004030 A MX2019004030 A MX 2019004030A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
glucocorticoid receptor
receptor inhibitors
useful
Prior art date
Application number
MX2019004030A
Other languages
English (en)
Other versions
MX385658B (es
Inventor
R Mcgee Lawrence
Eksterowicz John
C Medina Julio
Sun Daqing
Zhu Liusheng
Du Xiaohui
Yan Xuelei
Rew Yosup
R Fantin Valeria
Zhou Haiying
Delarae Balbas Minna
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2019004030A publication Critical patent/MX2019004030A/es
Publication of MX385658B publication Critical patent/MX385658B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere en general a composiciones y métodos para tratar el cáncer y el hipercortisolismo. En este documento se proporcionan compuestos derivados de esteroides sustituidos y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones en cuestión son útiles para la inhibición de los receptores de glucocorticoides. Además, los presentes compuestos y composiciones son útiles para el tratamiento del cáncer.
MX2019004030A 2016-10-07 2017-10-06 Inhibidores del receptor de glucocorticoides. MX385658B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US201762526331P 2017-06-28 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Publications (2)

Publication Number Publication Date
MX2019004030A true MX2019004030A (es) 2019-09-16
MX385658B MX385658B (es) 2025-03-18

Family

ID=61832215

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004030A MX385658B (es) 2016-10-07 2017-10-06 Inhibidores del receptor de glucocorticoides.
MX2021010252A MX2021010252A (es) 2016-10-07 2019-04-05 Inhibidores del receptor de glucocorticoides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010252A MX2021010252A (es) 2016-10-07 2019-04-05 Inhibidores del receptor de glucocorticoides.

Country Status (20)

Country Link
US (5) US10472387B2 (es)
EP (2) EP3851444A1 (es)
JP (2) JP6801093B2 (es)
KR (2) KR102237916B1 (es)
CN (2) CN110099915A (es)
AU (3) AU2017339510B2 (es)
BR (1) BR112019006987B1 (es)
CA (1) CA3039636C (es)
DK (1) DK3523315T3 (es)
ES (1) ES2867853T3 (es)
HU (1) HUE054542T2 (es)
IL (2) IL265835B (es)
MX (2) MX385658B (es)
NZ (1) NZ753142A (es)
PL (1) PL3523315T3 (es)
PT (1) PT3523315T (es)
SG (1) SG11201903055UA (es)
SI (1) SI3523315T1 (es)
WO (1) WO2018068021A1 (es)
ZA (1) ZA202004440B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
SG11201903055UA (en) 2016-10-07 2019-05-30 Oric Pharmaceuticals Inc Inhibitors of glucocorticoid receptor
CN112272552A (zh) * 2018-04-11 2021-01-26 欧瑞克制药公司 包含糖皮质激素受体拮抗剂的固体形式和制剂及其用途
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
WO2021226465A1 (en) * 2020-05-08 2021-11-11 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
JP3828926B2 (ja) 1993-08-04 2006-10-04 アクゾ・ノベル・エヌ・ベー 不安症の治療用抗グルココルチコイドステロイド
AU1439595A (en) 1993-12-22 1995-07-10 Salk Institute For Biological Studies, The Methods for reducing multidrug resistance
MX9603889A (es) 1995-02-02 1997-04-30 Schering Ag Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
EP1989218B1 (en) 2006-02-17 2009-12-30 Janssen Pharmaceutica, N.V. 17-phosphorous steroid derivatives useful as progesterone receptor modulators
CN101460467B (zh) 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
CA2684450C (en) 2007-04-20 2017-05-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
PL3912626T3 (pl) 2012-02-24 2025-01-20 The University Of Chicago Sposoby i kompozycje dotyczące antagonizmu wobec receptora glukokortykoidowego i nowotworu prostaty
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US10919929B2 (en) * 2013-12-11 2021-02-16 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
CA3009525A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
SG11201903055UA (en) 2016-10-07 2019-05-30 Oric Pharmaceuticals Inc Inhibitors of glucocorticoid receptor
US12233073B2 (en) 2017-06-09 2025-02-25 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
CN112272552A (zh) 2018-04-11 2021-01-26 欧瑞克制药公司 包含糖皮质激素受体拮抗剂的固体形式和制剂及其用途

Also Published As

Publication number Publication date
AU2021202016C1 (en) 2022-06-09
CA3039636C (en) 2023-04-11
AU2021202016A1 (en) 2021-04-29
EP3523315A1 (en) 2019-08-14
KR20210039001A (ko) 2021-04-08
US20230096870A1 (en) 2023-03-30
IL284005A (en) 2021-07-29
SI3523315T1 (sl) 2021-08-31
BR112019006987B1 (pt) 2021-05-04
SG11201903055UA (en) 2019-05-30
CA3039636A1 (en) 2018-04-12
EP3523315A4 (en) 2020-04-15
IL265835B (en) 2021-06-30
CN111690031B (zh) 2021-06-01
US20210017219A1 (en) 2021-01-21
JP2019533651A (ja) 2019-11-21
US10723759B2 (en) 2020-07-28
ES2867853T3 (es) 2021-10-21
NZ753142A (en) 2020-08-28
US20190218246A1 (en) 2019-07-18
IL265835A (en) 2019-06-30
WO2018068021A1 (en) 2018-04-12
PT3523315T (pt) 2021-04-29
HUE054542T2 (hu) 2021-09-28
EP3851444A1 (en) 2021-07-21
MX2021010252A (es) 2021-09-21
JP2021046409A (ja) 2021-03-25
CN111690031A (zh) 2020-09-22
US10472387B2 (en) 2019-11-12
CN110099915A (zh) 2019-08-06
AU2020213316A1 (en) 2020-08-27
KR20190083651A (ko) 2019-07-12
EP3523315B1 (en) 2021-03-24
BR112019006987A2 (pt) 2019-06-25
DK3523315T3 (da) 2021-05-03
AU2020213316B2 (en) 2021-03-11
US20200291058A1 (en) 2020-09-17
MX385658B (es) 2025-03-18
US20200055892A1 (en) 2020-02-20
ZA202004440B (en) 2022-07-27
AU2017339510B2 (en) 2020-07-30
PL3523315T3 (pl) 2021-10-18
AU2021202016B2 (en) 2022-01-06
KR102237916B1 (ko) 2021-04-09
JP6801093B2 (ja) 2020-12-16
AU2017339510A1 (en) 2019-05-23
US10836789B2 (en) 2020-11-17

Similar Documents

Publication Publication Date Title
MX2019004030A (es) Inhibidores del receptor de glucocorticoides.
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CO2018004750A2 (es) Composiciones para inhibir la actividad arginasa
ECSP17070706A (es) Inhibidores de bromodominio
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2017014375A (es) Moduladores del ccr2.
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
MX2017000450A (es) Compuestos terapeuticos inhibidores.
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
CO2017000363A2 (es) Inhibidores de la desmetilasa-1 específica de la lisina (lsd-1) derivados del [(5-carbonil)-1h-pirrol-3-il]-benzonitrilo o [(4-carbonil)imidazol-2-il]-benzonitrilo
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2018010993A (es) Derivados de icariina e icaritina.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas